The eligibility standards has been “over-restrictive,” she mentioned, limiting the quantity of people that can entry Paxlovid.
In contrast to the US, the place the drug has been a lot simpler to acquire, the Nationwide Institute for Well being and Care Excellence (NICE) really useful the antiviral was solely used for folks with critical underlying well being circumstances within the UK. This consists of HIV, most cancers, or transplant recipients.
“NICE has really useful that the eligible teams be expanded, however NHS England has pushed again on the implementation on account of capability points,” Prof Ritcher added. “The down aspect right here is many people who don’t get remedy will find yourself in secondary care, with penalties to them as people and trigger capability points elsewhere within the system.”
Antiviral drug resistance ‘an actual drawback’
Prof Paul Hunter, a professor in Drugs on the College of East Anglia, mentioned: “My private view is that we in all probability have been over slim.
“Age itself was not an indicator for its use within the UK, however I’d have included older age teams within the goal group even within the absence of one of many indicator ailments.”
But he added that there are reputable causes for a cautious rollout of Paxlovid, and mentioned a optimistic Covid check needs to be a prerequisite. Within the US, this requirement was dropped in 2023.
“Antiviral drug resistance is an actual drawback and though to this point, not an enormous drawback for Paxlovid and Covid, it’s only a matter of time – research have proven evolution of resistance is feasible,” he mentioned.
“So if very many individuals have been taking Paxlovid … it’s seemingly that resistance to the drug would develop extra quickly, after which it might now not be of such worth.”
Estimating the necessity was additionally tough, mentioned Marco Gallotta, an analyst at Airfinity. The antiviral grew to become accessible at a time when the omicron variant was surging internationally, triggering a brand new wave of illness.
“Governments have been eager to purchase the extremely efficacious antiviral and had a tough problem of estimating demand at a essential stage within the pandemic,” he mentioned. “This doesn’t essentially imply that larger uptake wasn’t fascinating and will have saved lives and hospitalisations, however the discount in testing decreased demand.”
The burden of illness has additionally fallen, whereas Paxlovid seems much less efficient in opposition to new strains of Covid. Even the US, which accounts for 54 per cent of reported gross sales to this point, negotiated a deal to return 7.9 million programs of unused Paxlovid in October.
Whereas Pfizer offered $19 billion of Paxlovid in 2022, this dropped to simply $1 billion in 2023.
“[By Airfinity’s figures], we purchased an excessive amount of and the Authorities is being criticised,” mentioned Prof Hunter. “But when we hadn’t purchased sufficient the Authorities would have been criticised maybe much more severely. Predicting demand was by no means going to be simple.”
The Telegraph has contacted the Division of Well being and Social Care.
Defend your self and your loved ones by studying extra about Global Health Security